MedTrace Logo

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

NCT00419536 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2010-04-08

No results posted yet for this study

Summary

This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.

Conditions

  • Hormone Refractory Prostate Cancer Disease

Interventions

DRUG

LBH589

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419536 on ClinicalTrials.gov